Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

11 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPR2c4OiCq MUPEUXNQ Ml;xTWM2OD1yLkCwNFA4KM7:TR?= MVyxO|k2PjB6MB?=
K562 NVvjTJEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHZPZBPPzJiaB?= MULEUXNQ MXLJR|UxRTBwMECxJO69VQ>? MV2xO|k2PjB6MB?=
M07e M2ftXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH6PJg4OiCq NYPXdHl2TE2VTx?= MmCxTWM2OD1yLkCwNVIh|ryP Ml;hNVc6PTZyOEC=
ALL3 Ml7wR5l1d3SxeHnjJGF{e2G7 M3H3eFAvOc7:TR?= MkjkO|IhcA>? NXv4eWl4TE2VTx?= Mn6wTWM2OD1yLkCwNFQh|ryP NEDrSIoyQTh6OUW0NC=>
CML Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS3SoozOCCvaX6= NVzCWHpLTE2VTx?= NFPLZlVKSzVyPUCuNFAyKM7:TR?= MlrwNVkzOTlyMU[=
BA/F3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrsbYo4PzJiaB?= MX3EUXNQ MmC2TWM2OD14LkW4PUDPxE1? MlKxNlMxQDh4NES=
BA/F3 Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrBO|IhcA>? NIfjSGxFVVOR MoK2TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MVOyN|A5QDZ2NB?=
BA/F3 M4f0TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX34PXlMPzJiaB?= NVewWHUyTE2VTx?= NUHpRmVrUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= M3TvVlI{ODh6NkS0
BA/F3 NEDJb|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWe3NkBp NV3t[mxjTE2VTx?= NH7WNY9KdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= M3rIOFI{ODh6NkS0
BA/F3 M4q5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYixU2pYPzJiaB?= NXzNN3U5TE2VTx?= M3voUGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP NYfYeZlwOjN|MEG3NFM>
BA/F3 NYfFV2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X1W|czKGh? Mo\NSG1UVw>? M3;TRWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP MmSxNlM{ODF5MEO=
BA/F3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjyTVI4OiCq M1Oyc2ROW09? MlnXTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? M3\LTFI{OzBzN{Cz
BA/F3 M3zS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvGRohRPzJiaB?= NID0SVBFVVOR MoPwTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhWTJ3MligcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwPO69VQ>? MkPXNlM{ODF5MEO=
BA/F3 NXLJdmNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXFO|IhcA>? NFjHTZhFVVOR MXLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? MXmyN|MxOTdyMx?=
BA/F3 MlfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{f4O|czKGh? NIToSHlFVVOR NHfBZ2ZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? NX\4XZZvOjN|MEG3NFM>
BA/F3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG2O|IhcA>? MVjEUXNQ MWLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? MoTtNlM{ODF5MEO=
BA/F3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYriNGVMPzJiaB?= MX3EUXNQ NHn2dnNKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? MkPWNlM{ODF5MEO=
BA/F3 NHHzc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvqO|IhcA>? M1nuS2ROW09? NXnXcFJ1UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN Mom2NlM{ODF5MEO=
T cell MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO3NkBp NIK0PXFFVVOR M4SzPGlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO MkPnNVcyPTR3MUK=
WiDr M4X6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzLeJA4OiCq MlfESG1UVw>? NIn3PXNKSzVyPUCuNFUzKM7:TR?= NGr4WY0yPTZzNUWxNi=>
PC3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf4bY1yPzJiaB?= NIO1U5RFVVOR MoHKTWM2OD1yLkCwPVQh|ryP Mn3JNVU3OTV3MUK=
MDA-MB-231 NFzTOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG3NkBp NVm1bmN{TE2VTx?= NF7aV2lKSzVyPUCuNFEzKM7:TR?= M1XVZlE2PjF3NUGy
Hs578T MlXpR5l1d3SxeHnjJGF{e2G7 Mn65O|IhcA>? MYXEUXNQ NX3Y[YZRT0l3ME2wMlA{KM7:TR?= NH7YNVAzPDBzNUOyOy=>
HMEC MUTDfZRwfG:6aXOgRZN{[Xl? NFzGOGU4OiCq NYjYbIh2TE2VTx?= MoPsS2k2OD1zLkig{txO NEPQdGQzPDBzNUOyOy=>
DU145 M3:wTWN6fG:2b4jpZ{BCe3OjeR?= M4izWlczKGh? M1PqVWROW09? M37sW2dKPTB;MD6xOkDPxE1? NHjCO3YzPDBzNUOyOy=>
U251 Mn\ER5l1d3SxeHnjJGF{e2G7 MXi3NkBp MkXwSG1UVw>? NVnONGhJT0l3ME2yMlgyKM7:TR?= M2X4d|I1ODF3M{K3
NCI60 M3L2UmN6fG:2b4jpZ{BCe3OjeR?= MmTDO|IhcA>? MVnEUXNQ NHLmXWdIUTVyPUWuO{DPxE1? NGHtSY0zPDBzNUOyOy=>
MALME-3M MWHDfZRwfG:6aXOgRZN{[Xl? MlW3O|IhcA>? MUHEUXNQ MWLHTVUxRTZwNkGg{txO NIPidmQzPDBzNUOyOy=>
KM12 MW\DfZRwfG:6aXOgRZN{[Xl? M3P2b|czKGh? MoDuSG1UVw>? MkH4S2k2OD15LkS0JO69VQ>? MVqyOFAyPTN{Nx?=
SW620 MXPDfZRwfG:6aXOgRZN{[Xl? NXS4WmJFPzJiaB?= M{TKXGROW09? MUfHTVUxRThwNEOg{txO NEDaSXYzPDBzNUOyOy=>
RXF 393NL M1jZfGN6fG:2b4jpZ{BCe3OjeR?= MkfXOEBl[Xm| MnzaSG1UVw>? MoDOTWM2OD1yLkCyNVch|ryP NGjSXIUzOzJ3M{C3OC=>
LXFA 983L NVTEPJFLS3m2b4TvfIlkKEG|c3H5 NFLUZ5Q1KGSjeYO= MYjEUXNQ MXjJR|UxRTBwMEW2OUDPxE1? MnvsNlMzPTNyN{S=
PRXF DU145 MUjDfZRwfG:6aXOgRZN{[Xl? M1mwflQh\GG7cx?= M2\GNmROW09? NFrMZ5FKSzVyPUCuNFYzOyEQvF2= M13rflI{OjV|MEe0
PAXF 1657L NYOy[mRYS3m2b4TvfIlkKEG|c3H5 M13tOlQh\GG7cx?= NGXMNppFVVOR NWC0Z5BrUUN3ME2wMlEzOSEQvF2= NVq4bHN2OjN{NUOwO|Q>
CXF 1103L Ml:yR5l1d3SxeHnjJGF{e2G7 M3HJ[VQh\GG7cx?= M2XFTGROW09? NVPVfpVDUUN3ME20MlM3KM7:TR?= NG\0fHEzOzJ3M{C3OC=>
GXF251L NYTKWnlbS3m2b4TvfIlkKEG|c3H5 MXS0JIRigXN? NVvXOIFQTE2VTx?= M1ewfmlEPTB;Mj6yOUDPxE1? Ml3ONlMzPTNyN{S=
NCI-H23 MmX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX1VI04OiCq NGfsTJhFVVOR NWTX[oFUUUN3ME2yMlI4KM7:TR?= M3O0dFI{PTJzMEKw
HCT116 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW3NkBp MlP1SG1UVw>? MlTQTWM2OD1{LkOg{txO MX6yN|UzOTB{MB?=
MCF7 NFn0ZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmOyO|IhcA>? MVLEUXNQ MX\JR|UxRTJwNUeg{txO NYrHV|RuOjN3MkGwNlA>
NCI-H460 NY\UPW1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK0RnY4OiCq NVjTZoFsTE2VTx?= MWfJR|UxRThwOUmg{txO MlS3NlM2OjFyMkC=
DLD1 MoXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF6zOYc4OiCq MYjEUXNQ MmLBTWM2OD12Lk[g{txO MnTFNlM2Pjd7NkC=
NCI-H661 Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDFNnc{PzJiaB?= NVXBXXlITE2VTx?= MknpTWM2OD15Lkig{txO MXyyN|U3Pzl4MB?=
A549 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3kO|IhcA>? NG[wNWhFVVOR NXvxPJBlUUN3ME24MlIh|ryP MlvrNlM2Pjd7NkC=
U937 NHPMSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\pNVczKGh? NHTtN4FFVVOR NF7LTldKSzVyPUGyMlIh|ryP NWrWV4hjOjN3Nke5OlA>
HEK293 NVnuPIhUTnWwY4Tpc44hSXO|YYm= M3G3SFExyqEQvF2= NIXQR3VFVVOR M3XBemlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN MU[yNlc4ODZzMB?=
HUVEC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKwMlE2yqEQvF2= MYG3NkBp MX\EUXNQ M{Tj[Glv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> MojRNlI5PTN7OUO=
HUVEC NFTVdpVHfW6ldHnvckBCe3OjeR?= NH\yclUyPcLizszN NVL1e5NVPzJiaB?= MYPEUXNQ NF7NdlFKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? M{SxRVIzQDV|OUmz
Plasmodium falciparum NES3O2xHfW6ldHnvckBCe3OjeR?= NWfUZWNEOTEEoN88US=> NUDZZ4FuOTVibXnu MVrEUXNQ NVzKU3JpUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP MlnLNlQ2PTB|M{C=
PC3 M3r1XmZ2dmO2aX;uJGF{e2G7 MYSwMlEh|ryP NEH6c|Y2KGh? NYD0WXUzTE2VTx?= NEO4W4hKdmirYnn0d{BpfW2jbjDQR|Mh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M{C4dlE6PDZ{OUe1
DU145 MUDGeY5kfGmxbjDBd5NigQ>? MlrrNE4yKM7:TR?= NIG1c3E2KGh? MmPMSG1UVw>? M4jue2lvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N M4nBbVE6PDZ{OUe1
PC3 M{GwOmtqdmG|ZTDBd5NigQ>? MX6wMlEh|ryP NETTUpg2KGh? M1LpZ2ROW09? M{T3XGlvcGmkaYTzJINUemNiaX6gbJVu[W5iUFOzJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= MoPNNVk1PjJ7N{W=
DU145 NF63eHdMcW6jc3WgRZN{[Xl? NVvEdGhWOC5zIN88US=> NIHMZnQ2KGh? NE\nWmFFVVOR M2PtPWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NHGzelAyQTR4Mkm3OS=>
PC3 MnPaT4lv[XOnIFHzd4F6 MVKwMlEh|ryP NGTQU|U2KGh? MXjEUXNQ MYjJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M3;BTVE6PDZ{OUe1
DU145 M3rlcWtqdmG|ZTDBd5NigQ>? M{PtTlAvOSEQvF2= MlvxOUBp NXLDe5hMTE2VTx?= NFvMNGxKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= MoLtNVk1PjJ7N{W=
Huh7 NXTv[VhpSW62aY\pdoFtKEG|c3H5 NEKxZlMzNjVizszN M4XwdVQh\GG7cx?= NE\VTmxFVVOR MWfJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? NI[wVJAyPzN4ME[3Oi=>
C6/36 NYTsNmlJSW62aY\pdoFtKEG|c3H5 M4fVN|IvPSEQvF2= M{f0U|Qh\GG7cx?= MnHCSG1UVw>? MWPJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIF{cWGwIITp[4VzKG2xc4H1bZRwKEN4L{O2JINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCxZjD2bZJidCCnbo\lcI9x\SCycn;0[YlvKHerdHjpckBx\XKrboXjcIVieiC{ZXfpc44h[XRiMj61JJVO M4j0TFE4OzZyNke2
U937 M4DBR2Z2dmO2aX;uJGF{e2G7 MoqyNUDPxE1? NX[3cYFqOSCq NW\tW3d[TE2VTx?= MUTS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MYGxO|Y5PDB7OR?=
U937 MnHaSpVv[3Srb36gRZN{[Xl? M2H4UVEh|ryP M3nIflEhcA>? MXHEUXNQ NUnCdlV3WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? M2jl[FE4Pjh2MEm5
murine mast cell MnjkSpVv[3Srb36gRZN{[Xl? MkH4NUDPxE1? MnHRNlQhcA>? NX;aWWgxTE2VTx?= M{fMSmlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP MXqxO|Y5PDB7OR?=
BV-173 NWHQVJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX3PGtKSzVyPUCuNFAxODByMUC5JO69VQ>? NWDrRXRtW0GQR1XS
K-562 MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf2TWM2OD1yLkCwNFAxODJ4NjFOwG0> MUPTRW5ITVJ?
BL-70 M2q1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTBwMECwNFAxQDJ{IN88US=> MkfUV2FPT0WU
EM-2 NF[yd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Pc|dKSzVyPUCuNFAxODBzMEig{txO Ml62V2FPT0WU
LAMA-84 NUi5NVhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnFfIVkUUN3ME2wMlAxODByM{KxJO69VQ>? NFjxUpdUSU6JRWK=
MEG-01 M3PYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfUTWM2OD1yLkCwNFAxQThizszN NH\yd2dUSU6JRWK=
EoL-1-cell NXm1WpVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HGZWlEPTB;MD6wNFAxOTNzIN88US=> NH36S2dUSU6JRWK=
CTV-1 NF\VV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV70WHBkUUN3ME2wMlAxODB2MESg{txO M{TkTnNCVkeHUh?=
TE-15 Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDCTWM2OD1yLkCwOVg6KM7:TR?= NXfWSY5IW0GQR1XS
NOS-1 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWX5XlNMUUN3ME2wMlAxPjF|IN88US=> NYjtZldOW0GQR1XS
D-336MG MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf5[nFKSzVyPUCuNFA3OyEQvF2= M1u3d3NCVkeHUh?=
LB1047-RCC NYjRXXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEC5PFkh|ryP NHLpVoZUSU6JRWK=
LB996-RCC Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTBwMEC5PVEh|ryP NWqwWJVUW0GQR1XS
SW982 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTYTWM2OD1yLkCxNVE2KM7:TR?= NFzMRYtUSU6JRWK=
TK10 NY[3Tms3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDmUXd[UUN3ME2wMlAyOTd2IN88US=> M3fET3NCVkeHUh?=
A704 M3LaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmroTWM2OD1yLkCxOFkyKM7:TR?= MljxV2FPT0WU
TE-8 NUTRO4ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXFdFZKSzVyPUCuNFE2PzZizszN MVvTRW5ITVJ?
DOHH-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP0UFlKSzVyPUCuNFE4OTlizszN NGfUNoJUSU6JRWK=
HOP-62 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj4TWM2OD1yLkCxPFM1KM7:TR?= NFmydopUSU6JRWK=
TE-12 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqdmlEPTB;MD6wNVg3OSEQvF2= M2LXWHNCVkeHUh?=
KGN M{LiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHr[oJ6UUN3ME2wMlAyQTR{IN88US=> NVTjfFlmW0GQR1XS
NCI-H1648 NHzKU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTUN5d{UUN3ME2wMlAzODFzIN88US=> NF\yU2pUSU6JRWK=
OS-RC-2 NH3KUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELuVHFKSzVyPUCuNFIxOyEQvF2= NWLsRmNTW0GQR1XS
GB-1 NXXNfXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm3UllKSzVyPUCuNFIyPTdizszN MoTnV2FPT0WU
RXF393 NX;1cnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTVUFVbUUN3ME2wMlAzOzV5IN88US=> NHnKZpFUSU6JRWK=
LC-2-ad NGrsO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5c4hyUUN3ME2wMlAzPTh4IN88US=> NF;UWVNUSU6JRWK=
KS-1 M4jWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LoXGlEPTB;MD6wNlc{KM7:TR?= NVnnc5ZqW0GQR1XS
ETK-1 NHPuU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon4TWM2OD1yLkCyPFMzKM7:TR?= NETFfFNUSU6JRWK=
SW954 NVfTPJBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7GT4NnUUN3ME2wMlAzQTJ5IN88US=> MWDTRW5ITVJ?
Becker MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Lkb2lEPTB;MD6wN|AxOyEQvF2= NWq2S2tqW0GQR1XS
MZ1-PC MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoGwTWM2OD1yLkCzNVE6KM7:TR?= MWfTRW5ITVJ?
ES6 MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTCTWM2OD1yLkCzNVk{KM7:TR?= NHPoW2JUSU6JRWK=
KURAMOCHI NY[yWFlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXSfmtQUUN3ME2wMlA{PDh5IN88US=> MUPTRW5ITVJ?
CGTH-W-1 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT2TWM2OD1yLkCzOVQ5KM7:TR?= M2L1bHNCVkeHUh?=
VA-ES-BJ M2TP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW2TWM2OD1yLkCzPVAzKM7:TR?= M2XOW3NCVkeHUh?=
LXF-289 NXvvXJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrqTWM2OD1yLkCzPVU3KM7:TR?= MXvTRW5ITVJ?
MPP-89 M{LWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3FTHd4UUN3ME2wMlA1ODR7IN88US=> MWXTRW5ITVJ?
SW872 M2WwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMESxOlEh|ryP M4T0bnNCVkeHUh?=
SNB75 NHL2fZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\TPXZKSzVyPUCuNFQ1OzVizszN Mni0V2FPT0WU
PSN1 NFTSfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMES0O|Qh|ryP M4rwW3NCVkeHUh?=
LB831-BLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP0VJlKSzVyPUCuNFQ3ODlizszN NVLM[Xk6W0GQR1XS
MFH-ino NH;INo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjZZXYxUUN3ME2wMlA1PzJ2IN88US=> NHK3NFRUSU6JRWK=
TGBC24TKB NXjQeoFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjWTWM2OD1yLkC0O|YyKM7:TR?= MoH0V2FPT0WU
A388 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\oTWM2OD1yLkC1NFk2KM7:TR?= MXPTRW5ITVJ?
BB30-HNC NWPKU45yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDSTWM2OD1yLkC1OFM4KM7:TR?= MX3TRW5ITVJ?
GI-ME-N NGTNOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr0TWM2OD1yLkC2NVE5KM7:TR?= NVnLR3pZW0GQR1XS
TGBC1TKB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD1yLkC2NVY1KM7:TR?= NFrLRW5USU6JRWK=
TE-10 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HQUGlEPTB;MD6wOlM2PyEQvF2= MlThV2FPT0WU
A498 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XidGlEPTB;MD6wO|I5PCEQvF2= Ml;MV2FPT0WU
TE-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEe4OVgh|ryP M3[3[nNCVkeHUh?=
BB65-RCC NYXO[|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTzfmVCUUN3ME2wMlA5OjJ5IN88US=> MVXTRW5ITVJ?
C2BBe1 NFe5fmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fnWGlEPTB;MD6wPFMxQCEQvF2= NELlS2RUSU6JRWK=
NCI-H747 M1rPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13LfWlEPTB;MD6wPFM3OiEQvF2= M3Lae3NCVkeHUh?=
IST-MES1 NX7aOWNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zLZWlEPTB;MD6wPFU2OiEQvF2= NYnndmVFW0GQR1XS
KALS-1 NFL2RYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jkUmlEPTB;MD6wPVQ6KM7:TR?= MkPKV2FPT0WU
GCIY M{nBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H1cWlEPTB;MD6wPVY2PiEQvF2= MX7TRW5ITVJ?
RL95-2 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq5[llKSzVyPUCuNVA{QCEQvF2= MX;TRW5ITVJ?
TE-1 NWL5SHdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mR|RKSzVyPUCuNVA2PCEQvF2= NWHDZ4RCW0GQR1XS
NCI-H1355 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjIemdKSzVyPUCuNVExOjhizszN M4f1fXNCVkeHUh?=
SW962 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPyeo9KSzVyPUCuNVEzQTJizszN M16zd3NCVkeHUh?=
KLE MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPRXINNUUN3ME2wMlEyOzF5IN88US=> Ml\ZV2FPT0WU
MC116 M4PrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTNTWM2OD1yLkGxOFEh|ryP MWfTRW5ITVJ?
NMC-G1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMUG2NFYh|ryP NF;IU3RUSU6JRWK=
KU812 M1rJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoK3TWM2OD1yLkGxPFg{KM7:TR?= NWrkXJNqW0GQR1XS
COLO-829 NGfUcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mny3TWM2OD1yLkGyNlE{KM7:TR?= NInzUZNUSU6JRWK=
NTERA-S-cl-D1 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnIeZUzUUN3ME2wMlEzOjh|IN88US=> NF;BbGFUSU6JRWK=
IST-MEL1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\JW4p6UUN3ME2wMlE{PDVizszN NUH6fJNOW0GQR1XS
MLMA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDZdYtTUUN3ME2wMlE1ODN{IN88US=> M1\YRnNCVkeHUh?=
LS-123 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUSwOlQh|ryP MkjHV2FPT0WU
LB2518-MEL MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXze2NUUUN3ME2wMlE1OTZ{IN88US=> M33HV3NCVkeHUh?=
NB69 M{PRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITVNZhKSzVyPUCuNVQ1OzZizszN MWDTRW5ITVJ?
8-MG-BA NXXTXpViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnNNZJKSzVyPUCuNVU1PThizszN NHHXSWJUSU6JRWK=
K5 NGDqOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMU[0PFkh|ryP MlnyV2FPT0WU
KINGS-1 NHnIWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{OzRWlEPTB;MD6xOlY3PiEQvF2= NVnsS2x2W0GQR1XS
SF268 M1XXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPYTWM2OD1yLkG3OFA1KM7:TR?= MVzTRW5ITVJ?
PF-382 NUjZbZg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLQTWM2OD1yLkG3Olc5KM7:TR?= M4TNZ3NCVkeHUh?=
SH-4 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMUi0NVMh|ryP MoWxV2FPT0WU
NALM-6 NVXydlMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PFTGlEPTB;MD6xPVI6PSEQvF2= MWjTRW5ITVJ?
CP66-MEL NVXxTmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;pS2lKSzVyPUCuNVk2OzFizszN NV3EUVlHW0GQR1XS
697 M{K3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXvTWM2OD1yLkG5PVg4KM7:TR?= M1izdHNCVkeHUh?=
CP67-MEL MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\ZdmlEPTB;MD6yNFQ5QCEQvF2= MVzTRW5ITVJ?
DSH1 NIPrdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;0O2lEPTB;MD6yOFAxOSEQvF2= MWrTRW5ITVJ?
HCE-4 NYP3U2lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjxSYFKSzVyPUCuNlY1OzlizszN NGD1coFUSU6JRWK=
MZ2-MEL Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVq4OohiUUN3ME2wMlI5PTN5IN88US=> MlnIV2FPT0WU
BL-41 NV;RNHNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH4dII3UUN3ME2wMlI6OTJ|IN88US=> M2XpfnNCVkeHUh?=
HUTU-80 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwM{G0NkDPxE1? MYnTRW5ITVJ?
LOXIMVI M13temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrEfYdCUUN3ME2wMlMyPTB|IN88US=> NXSySphzW0GQR1XS
no-10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS3TWM2OD1yLkOxPVMyKM7:TR?= NFHRe5RUSU6JRWK=
KARPAS-422 NWri[|RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mln0TWM2OD1yLkOzPVk4KM7:TR?= NEnmTmNUSU6JRWK=
SW684 NWjsPI01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DwbmlEPTB;MD6zOFk5KM7:TR?= MnnRV2FPT0WU
SF126 NVvnbZhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fWe2lEPTB;MD6zOVQyKM7:TR?= MkG0V2FPT0WU
D-263MG MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwM{[yNlQh|ryP Mk\vV2FPT0WU
OVCAR-4 NHKySnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHzdWFnUUN3ME2wMlM4PDN|IN88US=> MkfmV2FPT0WU
BB49-HNC NEjrN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfHOpFKSzVyPUCuN|g2QTlizszN NIfDUpJUSU6JRWK=
ONS-76 NWTiS5E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13RfWlEPTB;MD60Nlk2OSEQvF2= NFHVSoZUSU6JRWK=
MZ7-mel M2X2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PTS2lEPTB;MD60O|kyOSEQvF2= NWLxVnp4W0GQR1XS
RCC10RGB NYfVWlhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK5TWM2OD1yLkS5NVEh|ryP NH;xTmhUSU6JRWK=
BOKU NWPvd4RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDITWM2OD1yLkS5NVM{KM7:TR?= MnP4V2FPT0WU
no-11 Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWD4U|R2UUN3ME2wMlUxOjJ6IN88US=> NUD6bmk{W0GQR1XS
IST-SL2 NIL5eZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD1yLkWwN|AzKM7:TR?= MlS0V2FPT0WU
RKO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNUK5OlYh|ryP MXvTRW5ITVJ?
HT-144 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfaTWM2OD1yLkWzOlA6KM7:TR?= NEPBUZRUSU6JRWK=
NCI-H446 M3HZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzDfZFKSzVyPUCuOlI4PiEQvF2= NWSybIdbW0GQR1XS
QIMR-WIL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzVbJVKSzVyPUCuO|A3OjlizszN MknJV2FPT0WU
MHH-PREB-1 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[4dWlEPTB;MD63OFQ3QSEQvF2= MnzWV2FPT0WU
EW-16 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorFTWM2OD1yLke2NVc5KM7:TR?= MUXTRW5ITVJ?
EW-24 NGLyO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\RTWM2OD1yLke4NVY2KM7:TR?= NF3WTphUSU6JRWK=
LB373-MEL-D MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfRTWM2OD1yLkiyOVA5KM7:TR?= M3nk[3NCVkeHUh?=
TE-9 NH\qeYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjXTWM2OD1yLki3OVMzKM7:TR?= M1HZeHNCVkeHUh?=
A3-KAW NFGwVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\tTWM2OD1yLkm4OFUzKM7:TR?= NFXKeWRUSU6JRWK=
A101D MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHBTWM2OD1zLkCzNFQ{KM7:TR?= M3\hT3NCVkeHUh?=
OCUB-M MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwMES0NVIh|ryP NXqzbFRPW0GQR1XS
ES4 M{jkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFwMEWxOFUh|ryP MkD0V2FPT0WU
TE-6 M3PUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn6TWM2OD1zLkKxNlI3KM7:TR?= MXfTRW5ITVJ?
D-502MG M4G2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTFwMkOzO|Yh|ryP MmrFV2FPT0WU
KNS-42 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwMkS0NVIh|ryP NUXGOnE6W0GQR1XS
SNU-C2B NIqzZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPmRWQ3UUN3ME2xMlMxPTh7IN88US=> MkXzV2FPT0WU
NCI-H1838 M3XMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;iTWM2OD1zLkOwO|M{KM7:TR?= M1u5cHNCVkeHUh?=
NKM-1 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwM{C4OVkh|ryP NELLOpBUSU6JRWK=
GI-1 NG\O[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHCPXNGUUN3ME2xMlM3OjJizszN NXzGeJY5W0GQR1XS
NB5 NYrpcG0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwM{m4Nlch|ryP M323[nNCVkeHUh?=
CAS-1 M17DOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CwNWlEPTB;MT60NFk6OiEQvF2= NH;Nd|hUSU6JRWK=
HCE-T MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvreo9KSzVyPUGuOVY4OTRizszN MWHTRW5ITVJ?
SBC-1 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETJTodKSzVyPUGuOVc6QDRizszN MUfTRW5ITVJ?
JiyoyeP-2003 NH;hdnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrYTWM2OD1zLkezOFY3KM7:TR?= NFmyWldUSU6JRWK=
TE-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jPeGlEPTB;MT63PVE{QSEQvF2= NXvYWlRtW0GQR1XS
CAN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HlXGlEPTB;MT64NlI2OiEQvF2= MV3TRW5ITVJ?
SK-UT-1 M3O1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPuXYNKSzVyPUKuNVY3QTNizszN MX3TRW5ITVJ?
JVM-2 NE\Jd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHewdpRKSzVyPUKuN|YzQDRizszN M4DsfXNCVkeHUh?=
LB771-HNC NUDm[Wl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJwNUe1OVEh|ryP NHvBUZRUSU6JRWK=
NCCIT NU\6U3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwOE[2NVYh|ryP NYX4SVhCW0GQR1XS
NCI-H2126 NELabnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW4TWM2OD1{Lki3OVUzKM7:TR?= Ml\UV2FPT0WU
Calu-6 NXf5XpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;EN|JTUUN3ME2zMlA2PzRzIN88US=> M1XINXNCVkeHUh?=
SK-LMS-1 NIn6WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTq[XJVUUN3ME2zMlEyQDh4IN88US=> MYnTRW5ITVJ?
ARH-77 Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH4UIs{UUN3ME2zMlQ3QTF3IN88US=> NIPWR3dUSU6JRWK=
NB17 NFfHN|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnWSYNKSzVyPUOuOlM5PDdizszN NUPqbHFEW0GQR1XS
A253 M4D4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3jSJpvUUN3ME2zMlc{OjR4IN88US=> MVfTRW5ITVJ?
OPM-2 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjBTWM2OD12LkK3Olg2KM7:TR?= NUfsR|NkW0GQR1XS
MV-4-11 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTnZ252UUN3ME20MlM3PDV2IN88US=> NI\IWWdUSU6JRWK=
SR NIDUXHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnjPYpKSzVyPUSuOFk6PTRizszN MUDTRW5ITVJ?
KG-1 M3;wWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfte2NKSzVyPUSuOlA5PDVizszN MXXTRW5ITVJ?
OCI-AML2 Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3IXWtKSzVyPUWuPFYyPTRizszN M3LVRnNCVkeHUh?=
D-247MG NUL5OYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ruTGlEPTB;Nj6xNlUyQSEQvF2= NEDyXY5USU6JRWK=
DJM-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHRd|J6UUN3ME22MlQ5PTV6IN88US=> NVSwS2FDW0GQR1XS
RPMI-6666 NULST2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H3UmlEPTB;Nz6yO|A3PyEQvF2= MVXTRW5ITVJ?
KARPAS-45 NVvsXZdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK4TWM2OD15LkWxOlcyKM7:TR?= MnnTV2FPT0WU
LP-1 MoWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTdwNUS3PFIh|ryP MlXHV2FPT0WU
RS4-11 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTdwNkW3PFch|ryP MkDxV2FPT0WU
DU-4475 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrjTWM2OD16LkKxOlUzKM7:TR?= M1HqSHNCVkeHUh?=
MONO-MAC-6 NH3VVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml34TWM2OD16LkK3NFY3KM7:TR?= MX\TRW5ITVJ?
NCI-SNU-16 NETTeJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRThwNU[xNlgh|ryP NVfRenB6W0GQR1XS
SJSA-1 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\pTZZKSzVyPUiuO|I5ODVizszN MojTV2FPT0WU
MMAC-SF NIDv[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX4N4NZUUN3ME24Mlc6OzB5IN88US=> MkXkV2FPT0WU
SK-NEP-1 NXOyUWN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjnNoFKSzVyPUiuPFkyPTVizszN NWPMOHNGW0GQR1XS
J-RT3-T3-5 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\aZmtKSzVyPUiuPVY2OjlizszN M4\MZnNCVkeHUh?=
SKM-1 NYXXeHJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7sSYRoUUN3ME25MlAyPzN2IN88US=> MWTTRW5ITVJ?
LB2241-RCC NUK4fnpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTlwMEKwNVIh|ryP M1rBOHNCVkeHUh?=
SIG-M5 NVnPeFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjGdmM5UUN3ME25MlAzPDl|IN88US=> NVv2SYVTW0GQR1XS
EVSA-T NYrXbpRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnoTWM2OD17LkK3O|k{KM7:TR?= MkXOV2FPT0WU
GT3TKB Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37ZWWlEPTB;OT6zOVU1PiEQvF2= M1e0[XNCVkeHUh?=
NB6 MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS2TWM2OD17LkmyNlU6KM7:TR?= NYHzblRqW0GQR1XS
EHEB M{LyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvjNXFKSzVyPUGwMlA3PTZizszN Mn\uV2FPT0WU
HEL NIPhcFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjpdFFQUUN3ME2xNE41Pzd4IN88US=> NGTIN29USU6JRWK=
ALL-PO NHHXOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDw[VJ5UUN3ME2xNE44QTN6IN88US=> NF;yfmVUSU6JRWK=
TGW MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LXTmlEPTB;MUGuNlgzQCEQvF2= M1;HO3NCVkeHUh?=
BC-3 M1vxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7zTWM2OD1zMj6xNVM5KM7:TR?= MVjTRW5ITVJ?
IA-LM M4iyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF{LkS0OFUh|ryP MUXTRW5ITVJ?
UACC-257 NXSwb5ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrsN2lKSzVyPUGyMlkyQThizszN M4fLNXNCVkeHUh?=
KP-N-YS MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF{LkmyPFMh|ryP MknWV2FPT0WU
Raji NXSxSYdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF|Lke0PVch|ryP MkLMV2FPT0WU
SF539 NV\pOnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD2TWM2OD1zMz64OVU4KM7:TR?= Mkn1V2FPT0WU
DMS-153 NV\xd5JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\BRWlEPTB;MUSuNFAzQCEQvF2= MWHTRW5ITVJ?
L-540 NH63fZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTF3LkC2O|Ih|ryP MoS3V2FPT0WU
MN-60 M2Hhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF3LkG5O|kh|ryP NELSZnBUSU6JRWK=
RPMI-8866 NHvBb4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrHTWM2OD1zNz60OFU1KM7:TR?= NWjlfZJJW0GQR1XS
NCI-H510A MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\i[mlEPTB;MUmuN|k4OyEQvF2= MoLnV2FPT0WU
NB13 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\3WlN6UUN3ME2xPU41QDd5IN88US=> Mni4V2FPT0WU
HAL-01 M4CwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPKPZBKSzVyPUG5Mlc2PDNizszN Mn7SV2FPT0WU
NCI-H720 Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTPXlF2UUN3ME2yNE4zPzN|IN88US=> NITC[mFUSU6JRWK=
REH M1S3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoS5TWM2OD1{MD62N|U4KM7:TR?= NHqyfnhUSU6JRWK=
KNS-81-FD MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jsc2lEPTB;MkOuNVQ3KM7:TR?= NUTX[5h3W0GQR1XS
HC-1 M2T3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;KR4RKSzVyPUK0MlU2PTFizszN NIGy[VhUSU6JRWK=
NCI-H2141 M1XXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ2Lke3OVQh|ryP NXnOdY1WW0GQR1XS
MOLT-4 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCzTYhFUUN3ME2yOk43PzV|IN88US=> NHThTFNUSU6JRWK=
OMC-1 M2rlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;1TWM2OD1{Nz6xOFIzKM7:TR?= NFLqeXRUSU6JRWK=
LC-1F NUPKXHdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fuNmlEPTB;MkeuN|I1PSEQvF2= NF3lNZhUSU6JRWK=
NCI-H1304 MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTIbmY2UUN3ME2yPE4yPjJ6IN88US=> NUDFcmRKW0GQR1XS
BC-1 NVLsNnNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDTOpBKSzVyPUK4MlY2OSEQvF2= MYDTRW5ITVJ?
NCI-H64 MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnPTYVKSzVyPUK5MlYzPTNizszN MYPTRW5ITVJ?
MOLT-16 NVHSbFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:yNmlEPTB;MkmuOlI6OiEQvF2= MX3TRW5ITVJ?
U-87-MG MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jkXWlEPTB;M{CuO|Y3KM7:TR?= M1rXRXNCVkeHUh?=
GAK NWSzU41XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvyVpJKSzVyPUOxMlI3QDZizszN MV\TRW5ITVJ?
ES8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTN{LkGyOVIh|ryP NF\nXmdUSU6JRWK=
HCC1599 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\ZfpdOUUN3ME2zNk4{OzJ3IN88US=> NHLVXm9USU6JRWK=
EB-3 MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXhOXQyUUN3ME2zOE4{OTF5IN88US=> NGXUc2tUSU6JRWK=
HCC1187 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN3LkiwOVIh|ryP MkDXV2FPT0WU
SK-PN-DW NWq2SGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnoPGJmUUN3ME2zOk4yQTR|IN88US=> Ml3SV2FPT0WU
JVM-3 NUXWPZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjHTWM2OD1|Nz6yN|M5KM7:TR?= NEjifGdUSU6JRWK=
HCC2157 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTN5Lkm5OFYh|ryP MVvTRW5ITVJ?
A4-Fuk NUW0RokzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX3TWM2OD1|OD6xNFA6KM7:TR?= NYjrZ4ZYW0GQR1XS
COR-L279 M{f2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KyRmlEPTB;NECuNlg2OSEQvF2= MWHTRW5ITVJ?
DEL M{f6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLXTWM2OD12MT65NFg3KM7:TR?= NWSwW5NTW0GQR1XS
NCI-H1395 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX2xU41[UUN3ME20Nk4xOTZ|IN88US=> M{L5W3NCVkeHUh?=
MHH-NB-11 M2\4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTR|LkC4NVgh|ryP MXjTRW5ITVJ?
NCI-H2107 NEPWOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHCTWM2OD12Mz60PFQ3KM7:TR?= NInrNmhUSU6JRWK=
NEC8 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzaSYFKSzVyPUS0MlM{PiEQvF2= MkHlV2FPT0WU
COLO-684 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjMTWM2OD12Nj6yNlU5KM7:TR?= MmDqV2FPT0WU
LS-411N M{G1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfI[GxxUUN3ME20PE41PzR6IN88US=> M3;JenNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID